Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15804430 | 0.91 | PLA2G7 (0.41) | PLA2G7MAPTMDM2GPR119 | |
| SCHEMBL15692202 | 0.80 | MAPT (0.40) | MAPTKDM4EMEN1HSP90AA1CRHBP | |
| SCHEMBL14476743 | 0.79 | MAPT (0.39) | MAPTKDM4EMEN1HSP90AA1CRHBP | |
| SCHEMBL14476259 | 0.79 | PLA2G7 (0.41) | PLA2G7MAPTKDM4EALDH1A1MDM2 | |
| SCHEMBL14476256 | 0.78 | PLA2G7 (0.40) | PLA2G7MAPTKDM4EALDH1A1MDM2 | |
| SCHEMBL14476609 | 0.77 | MEN1 (0.39) | MAPTKDM4EMEN1HSP90AA1CRHBP | |
| SCHEMBL14476255 | 0.74 | PLA2G7 (0.38) | PLA2G7MAPTKDM4EALDH1A1MDM2 | |
| SCHEMBL17629541 | 0.74 | KCNQ2 (0.48) | MAPTKDM4EMEN1HSP90AA1CRHBP | |
| SCHEMBL14476262 | 0.73 | PLA2G7 (0.51) | PLA2G7TRPM2 | |
| SCHEMBL15654157 | 0.71 | ROCK2 (0.40) | MAPTTRPM2ALDH1A1MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2014-06-19 | — | — | US | disclosed |
| WO-2013000108-A1 | AZOLE HETEROCYLIC COMPOUNDS, PREPARATION METHODS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 中国科学院上海药物研究所 (CN) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171431-A1 | AZOLE HETEROCYCLIC COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | PLA2G5, LTA4H, PLA2G4A | PLA2G7 10/4885MAPT 4529/4885KDM4E 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.